The non-alcoholic steatohepatitis clinical trials market size was valued at USD 2.97 billion in 2025 and is projected to grow from USD 3.15 billion in 2026 to USD 5.10 billion by 2034, registering a CAGR of 6.23% during the forecast period (2026–2034). North America dominated the non-alcoholic steatohepatitis clinical trials market with a market share of 48.92% in 2025.
Non-alcoholic steatohepatitis clinical trials involve the evaluation of investigational therapies aimed at treating liver inflammation, fibrosis, and metabolic dysfunction associated with NASH. These trials assess the safety, efficacy, and long term outcomes of drug candidates across different clinical phases. They are supported by pharmaceutical companies, research organizations, and healthcare institutions to address the growing burden of chronic liver diseases.
The non-alcoholic steatohepatitis clinical trials market demand is increasing due to the rising prevalence of obesity and metabolic disorders, along with growing investments in drug development and regulatory support. Advancements in biomarkers, imaging technologies, and precision medicine approaches, coupled with increasing collaborations among industry participants, are further contributing to market growth.
Download a Free Sample To learn more about this report,
The non-alcoholic steatohepatitis clinical trials market is indirectly exposed to supply chain disruptions due to its dependence on global networks for investigational drug manufacturing, clinical trial materials, laboratory supplies, and logistics. Disruptions in the procurement of active pharmaceutical ingredients, diagnostic kits, and clinical research equipment can delay patient enrollment, trial execution, and regulatory timelines across multiple regions. The market is demonstrating a stair-step recovery, supported by diversified supplier networks, decentralized clinical trial models, digital monitoring technologies, and strategic investments in resilient global clinical research infrastructure.
AI-Driven Biomarker Integration
The growing adoption of artificial intelligence is changing how non-alcoholic steatohepatitis clinical trials identify eligible patients and monitor disease progression. Trial sponsors are increasingly integrating AI-based imaging analysis, digital pathology, and biomarker-driven patient stratification to improve trial efficiency and reduce screen failure rates. This transition is enabling more accurate endpoint assessment, faster recruitment, and improved decision-making throughout clinical development. For example, Perspectum uses AI-powered imaging technologies to support liver disease assessment and patient selection in NASH research.
Rising Adoption of Combination Therapies is Reshaping Clinical Development
Increasing understanding of the complex mechanisms underlying NASH is driving a shift from single-drug approaches toward combination therapy clinical trials. Pharmaceutical companies are evaluating therapies targeting fibrosis, inflammation, and metabolic dysfunction simultaneously to improve treatment outcomes and address diverse patient populations. This transition is expanding collaborative research strategies and creating more comprehensive clinical development programs across the industry.
The non-alcoholic steatohepatitis clinical trials market forecasts continued investment activity driven by the increasing prevalence of metabolic liver diseases, growing pharmaceutical interest in fibrosis-targeted therapies, and expanding late-stage clinical development programs. In 2025, Madrigal Pharmaceuticals secured a senior secured credit facility of up to USD 500 million from funds managed by Blue Owl Capital. The financing is intended to support the expansion of the company's MASH pipeline, accelerate ongoing and future clinical development programs, and strengthen its commercial and research capabilities.
Increasing Use of Non-invasive Biomarkers and Expansion of Combination Therapy Development Drives Market
The growing adoption of non-invasive biomarkers and imaging technologies is driving the non-alcoholic steatohepatitis clinical trials market by reducing dependence on repeated liver biopsies during patient screening and monitoring. Advanced MRI-PDFF, transient elastography, and blood-based biomarkers enable faster identification of eligible patients and improve participant retention throughout clinical studies. This shortens enrollment timelines and enhances operational efficiency for sponsors conducting global multicenter trials.
The increasing focus on combination therapies is driving the market by creating demand for more complex and larger clinical studies. Since NASH involves fibrosis, inflammation, and metabolic dysfunction, developers are evaluating multiple mechanisms of action within a single treatment regimen to improve efficacy. This has increased the number of adaptive trial designs, dose-combination studies, and global Phase II and III programs.
Dependence on Liver Biopsy Endpoints and High Clinical Trial Failure Rates Restrain Market Expansion
The continued reliance on liver biopsy as a primary efficacy endpoint restrains the non-alcoholic steatohepatitis clinical trials market by increasing trial complexity and patient burden. Biopsy procedures are invasive, costly, and often discourage patient participation and long-term follow-up. This leads to slower enrollment, higher dropout rates, and extended study timelines.
The high failure rate of investigational NASH therapies and evolving regulatory expectations increases development risks for sponsors. Many drug candidates fail to demonstrate meaningful improvements in fibrosis or NASH resolution during late-stage studies, resulting in program discontinuation and financial losses. This reduces investment confidence and delays the introduction of new therapies.
Decentralized and Virtual Clinical Trial Models and Increasing Strategic Licensing and Co-development Agreements Offer Growth Opportunities to Market Players
The increasing adoption of decentralized and hybrid clinical trial models creates a significant growth opportunity for sponsors, CROs, and digital health providers in the non-alcoholic steatohepatitis clinical trials market. Remote patient monitoring, telemedicine, and electronic patient-reported outcomes improve recruitment, retention, and access to geographically diverse patient populations. This is expected to accelerate global trial execution while reducing operational costs and improving participant engagement.
The rising number of licensing, co-development, and commercialization agreements creates significant growth opportunities for pharmaceutical companies and biotechnology firms. Large pharmaceutical companies are partnering with smaller innovators to access promising NASH drug candidates, share development risks, and accelerate global clinical programs. This trend is expected to expand late-stage trial activity, strengthen pipeline diversification, and increase cross-border collaborations.
Lack of Validated Surrogate Endpoints and Evolving Disease Nomenclature Challenges Market Growth
The absence of universally accepted surrogate endpoints continues to challenge the non-alcoholic steatohepatitis clinical trials market. Sponsors must generate extensive long-term clinical evidence to demonstrate meaningful improvements in fibrosis and disease progression, extending study duration and increasing development costs.
The transition from NASH to MASH and the adoption of updated diagnostic criteria are creating challenges in standardizing ongoing and future clinical trials. Sponsors must align trial protocols, patient classification methods, and clinical documentation with evolving medical guidelines while maintaining consistency across global study sites.
Request Customizationto receive a tailored report.
The phase III segment accounted for a share of 51.29% in 2025, owing to confirmatory efficacy and safety assessments required for regulatory submissions, and substantial sponsor investments before commercialization.
The phase I is expected to grow at a CAGR of around 6.87% during the forecast period due to increasing first-in-human evaluations of novel therapeutic targets, expansion of early-stage biotechnology pipelines, and rising exploration of combination therapies. Growing innovation in metabolic disease drug discovery continues to accelerate Phase I trial initiation worldwide.
In 2025, interventional studies accounted for a share of 45.61% in 2025. This is due to regulatory requirements for controlled efficacy evaluation and widespread assessment of investigational therapies targeting fibrosis and metabolic dysfunction. These studies remain essential for generating clinical evidence supporting drug approvals.
The observational studies segment is expected to grow at a CAGR of 7.59% during the forecast period, driven by increasing use of long-term disease progression monitoring and broader adoption of patient registries following therapeutic approvals.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Strong Clinical Research Infrastructure and High Concentration of Late-stage NASH Drug Development
The North America non-alcoholic steatohepatitis clinical trials market accounted for the largest regional share of 48.92% in 2025, driven by established clinical research ecosystem, high concentration of biotechnology and pharmaceutical companies, and widespread availability of specialized hepatology centers. The high prevalence of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH) continues to strengthen patient recruitment for multicenter clinical trials across the US and Canada.
The US non-alcoholic steatohepatitis clinical trials market was valued at USD 1.27 billion in 2025, driven by the presence of leading drug developers, extensive Phase II and Phase III clinical trial activity, and strong investment in metabolic disease research. The country hosts a large network of academic medical centers, liver disease specialists, and clinical research organizations that support rapid patient enrollment and execution of complex multicenter studies. Continued regulatory support and increasing adoption of decentralized clinical trial approaches further strengthen the country's leadership in global NASH clinical development.
The non-alcoholic steatohepatitis clinical trials market in Canada was valued at USD 185.90 million in 2025, supported by expanding participation in multinational clinical studies and increasing investment in hepatology research. Canadian healthcare institutions provide access to diverse patient populations, robust research ethics frameworks, and advanced clinical infrastructure that facilitate high-quality trial execution.
Asia Pacific: Fastest Growth Driven by Expanding Treatment-Naive Patient Pool and Increasing Participation in Global Multiregional Clinical Trials
The Asia Pacific non-alcoholic steatohepatitis clinical trials market is expected to grow at a CAGR of 8.06% during the forecast period, showcasing the fastest regional growth. Growth is supported by large treatment-naive patient population, increasing participation in global multiregional clinical trials, and rising investment in metabolic disease research. The region is becoming an attractive destination for clinical trial sponsors due to faster patient recruitment, lower trial execution costs, and expanding Good Clinical Practice-compliant research centers.
The China non-alcoholic steatohepatitis clinical trials market was valued at USD 157.09 million in 2025, supported by expansion of Hospital Phase I Clinical Trial Centers under China's National Medical Products Administration (NMPA) accreditation framework and the country's increasing integration of Hospital Information Systems and electronic medical records for rapid patient identification. The widespread adoption of the HAINAN Boao Lecheng International Medical Tourism Pilot Zone for early access to innovative therapies and China's extensive network of Grade III hospitals continue to attract multinational sponsors conducting MASH/NASH clinical trials.
The India non-alcoholic steatohepatitis clinical trials market was valued at USD 80.35 million in 2025, fueled by the country's high burden of lean NAFLD/NASH, a distinct phenotype commonly observed in the Indian population that is attracting global clinical research interest. The expansion of dedicated liver institutes such as the Institute of Liver and Biliary Sciences and increasing participation of Apollo Hospitals, AIG Hospitals, and Medanta in multinational hepatology trials are strengthening India's position as a key destination for NASH clinical development.
The Japan non-alcoholic steatohepatitis clinical trials market was valued at USD 92.71 million in 2025, supported by advanced translational research capabilities, strong integration of pharmaceutical companies with academic hepatology centers, and increasing use of precision medicine approaches in liver disease research. The country's emphasis on high-quality clinical data generation and biomarker-driven therapeutic development continues to attract innovative NASH clinical programs from both domestic and international sponsors.
Unlock Regional Insightsto access country-level data, & regional trends.
The non-alcoholic steatohepatitis clinical trials market competitive landscape is moderately fragmented, with participation from large pharmaceutical companies, biotechnology firms, CROs, and academic research institutions. Established players compete primarily through diversified clinical pipelines, global multicenter trial capabilities, strategic collaborations, regulatory expertise, and strong financial resources that enable large scale Phase II and Phase III studies. Emerging companies focus on developing novel therapeutic mechanisms, precision medicine approaches, and innovative combination therapies to differentiate their pipelines. The market ecosystem is also shaped by licensing agreements, co-development partnerships, and investments in advanced diagnostic technologies that improve patient selection and clinical trial efficiency.
July 2026: Madrigal Pharmaceuticals announced the grant of three new patents covering Rezdiffra (resmetirom), strengthening its intellectual property portfolio and extending protection for its MASH franchise.
September 2025: 89bio announced that it had entered into a definitive merger agreement with Roche, under which Roche agreed to acquire the company for a total equity value of up to USD 3.5 billion, strengthening Roche's liver disease pipeline.
August 2025: Madrigal Pharmaceuticals received European Commission conditional marketing authorization for Rezdiffra (resmetirom) for the treatment of adults with MASH and moderate-to-advanced liver fibrosis, marking the first approved therapy for MASH in the European Union.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com